Atara Biotherapeutics (NASDAQ:ATRA) Stock Rating Upgraded by ValuEngine

Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, ValuEngine reports.

A number of other brokerages have also issued reports on ATRA. Zacks Investment Research raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 16th. Jefferies Financial Group lowered shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating and decreased their target price for the company from $32.00 to $15.00 in a research note on Monday, September 16th. Goldman Sachs Group lowered shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and decreased their target price for the company from $14.00 to $9.00 in a research note on Friday, September 27th. BidaskClub lowered shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Friday, September 27th. Finally, Canaccord Genuity reissued a “buy” rating and set a $70.00 target price on shares of Atara Biotherapeutics in a research note on Monday, July 1st. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the stock. Atara Biotherapeutics currently has a consensus rating of “Hold” and a consensus price target of $29.75.

Atara Biotherapeutics stock traded up $0.22 during midday trading on Wednesday, reaching $14.08. The stock had a trading volume of 379,733 shares, compared to its average volume of 675,715. The firm’s fifty day simple moving average is $14.14 and its two-hundred day simple moving average is $22.51. Atara Biotherapeutics has a twelve month low of $11.50 and a twelve month high of $43.94. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.80 and a quick ratio of 7.80. The firm has a market cap of $756.91 million, a price-to-earnings ratio of -2.67 and a beta of 2.09.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.45) by ($0.15). As a group, sell-side analysts predict that Atara Biotherapeutics will post -5.71 EPS for the current fiscal year.

In other news, insider Joe Newell sold 3,500 shares of the firm’s stock in a transaction on Friday, September 27th. The shares were sold at an average price of $13.51, for a total transaction of $47,285.00. Following the transaction, the insider now owns 57,998 shares in the company, valued at approximately $783,552.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.00% of the stock is currently owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in ATRA. Maverick Capital Ltd. raised its holdings in shares of Atara Biotherapeutics by 156.4% during the 2nd quarter. Maverick Capital Ltd. now owns 2,232,476 shares of the biotechnology company’s stock valued at $44,895,000 after purchasing an additional 1,361,712 shares in the last quarter. FMR LLC raised its holdings in shares of Atara Biotherapeutics by 21.7% during the 1st quarter. FMR LLC now owns 6,417,956 shares of the biotechnology company’s stock valued at $255,114,000 after purchasing an additional 1,143,787 shares in the last quarter. Morgan Stanley raised its holdings in shares of Atara Biotherapeutics by 55.8% during the 2nd quarter. Morgan Stanley now owns 1,997,538 shares of the biotechnology company’s stock valued at $40,171,000 after purchasing an additional 715,077 shares in the last quarter. Baupost Group LLC MA raised its holdings in shares of Atara Biotherapeutics by 9.7% during the 2nd quarter. Baupost Group LLC MA now owns 7,000,000 shares of the biotechnology company’s stock valued at $140,770,000 after purchasing an additional 619,481 shares in the last quarter. Finally, BlackRock Inc. raised its holdings in shares of Atara Biotherapeutics by 10.2% during the 2nd quarter. BlackRock Inc. now owns 3,841,451 shares of the biotechnology company’s stock valued at $77,252,000 after purchasing an additional 357,026 shares in the last quarter. Institutional investors and hedge funds own 91.79% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Story: What is the return on assets formula?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.